Mineralys Therapeutics Inc (MLYS)

Feb 18, 2025

Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MSN

Feb 18, 2025

Feb 18, 2025

When the Price of (MLYS) Talks, People Listen - Stock Traders Daily

Feb 18, 2025

Feb 17, 2025

Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Feb 17, 2025

Feb 15, 2025

The Goldman Sachs Group Has Lowered Expectations for Mineralys Therapeutics (NASDAQ:MLYS) Stock Price - Defense World

Feb 15, 2025

Feb 15, 2025

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Defense World

Feb 15, 2025

Feb 14, 2025

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down Following Analyst Downgrade - MarketBeat

Feb 14, 2025

Feb 14, 2025

Mineralys Therapeutics' (MLYS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Feb 14, 2025

Feb 14, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2024 Earnings Call Transcript - MSN

Feb 14, 2025

Feb 14, 2025

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down on Analyst Downgrade - Defense World

Feb 14, 2025

Feb 14, 2025

Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat - MSN

Feb 14, 2025

Feb 13, 2025

Mineralys Therapeutics Highlights Positive Earnings Call - TipRanks

Feb 13, 2025

Feb 13, 2025

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat

Feb 13, 2025

Feb 13, 2025

Mineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Feb 13, 2025

Feb 13, 2025

Promising Outlook for Mineralys Therapeutics: Buy Rating Affirmed on Lorundrostat’s Potential - TipRanks

Feb 13, 2025

Feb 13, 2025

Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime - MyChesCo

Feb 13, 2025

Feb 13, 2025

Earnings call transcript: Mineralys Therapeutics Q4 2024 misses EPS forecast By Investing.com - Investing.com Australia

Feb 13, 2025

Feb 12, 2025

Mineralys Therapeutics Reports 2024 Earnings and Trial Progress - TipRanks

Feb 12, 2025

Feb 12, 2025

Mineralys outlines pivotal trial timelines for lorundrostat in hypertension - MSN

Feb 12, 2025

Feb 12, 2025

Earnings call transcript: Mineralys Therapeutics Q4 2024 misses EPS forecast - Investing.com India

Feb 12, 2025

Feb 12, 2025

Mineralys Therapeutics : Corporate Overview February 2025 - Marketscreener.com

Feb 12, 2025

Feb 12, 2025

Promising Growth Ahead: Mineralys Therapeutics Positioned for Success with Robust Financials and Key Hypertension Study Results - TipRanks

Feb 12, 2025

Feb 12, 2025

Mineralys Therapeutics Inc. (MLYS) reports earnings - Quartz

Feb 12, 2025

Feb 12, 2025

Mineralys Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 12, 2025

Feb 12, 2025

MINERALYS THERAPEUTICS Earnings Results: $MLYS Reports Quarterly Earnings - Nasdaq

Feb 12, 2025

Feb 12, 2025

Mineralys Therapeutics Announces Clinical Trial Updates and Fourth Quarter 2024 Financial Results - Nasdaq

Feb 12, 2025

Feb 12, 2025

Mineralys Financial Results Reveal Strong Pipeline Progress: 3 Major Clinical Readouts Coming in 2025 - StockTitan

Feb 12, 2025

Feb 12, 2025

Mineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

Feb 12, 2025

Feb 11, 2025

Palvella Therapeutics Expands Phase 3 Trial to Younger Patients - MyChesCo

Feb 11, 2025

Feb 09, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by Jennison Associates LLC - MarketBeat

Feb 09, 2025

Feb 08, 2025

Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Feb 08, 2025

Feb 08, 2025

Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Stock Has Dropped -21.18% Over The Month – Is There Room For Growth? - Marketing Sentinel

Feb 08, 2025

Feb 08, 2025

Mineralys Therapeutics Inc (NASDAQ: MLYS): Can The Stock Still Lose Despite An -20.31% YTD Loss? - Marketing Sentinel

Feb 08, 2025

Feb 08, 2025

Mineralys Therapeutics (MLYS) to Release Earnings on Wednesday - Defense World

Feb 08, 2025

Feb 07, 2025

Allarity Therapeutics advances ovarian cancer drug trial - MSN

Feb 07, 2025

Feb 07, 2025

Long Term Trading Analysis for (MLYS) - Stock Traders Daily

Feb 07, 2025

Feb 07, 2025

Clinical Trials News Live Feed - StockTitan

Feb 07, 2025

Feb 07, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by SG Americas Securities LLC - Defense World

Feb 07, 2025

Feb 07, 2025

Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MSN

Feb 07, 2025

Feb 07, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Mineralys Therapeutics, Inc.(MLYS) Investors to Inquire about Securities Investigation - ACCESS Newswire

Feb 07, 2025

Feb 05, 2025

Hypertension Drug Developer Mineralys Therapeutics Announces Critical Q4 Earnings Date - StockTitan

Feb 05, 2025

Feb 05, 2025

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 - Marketscreener.com

Feb 05, 2025

Feb 05, 2025

Mineralys Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 - Nasdaq

Feb 05, 2025

Feb 05, 2025

Mineralys Therapeutics to Announce Fourth Quarter and Full - GlobeNewswire

Feb 05, 2025

Feb 04, 2025

Mineralys Completes Enrollment In Phase 2 Explore-CKD Trial Of Lorundrostat For Hypertension - Nasdaq

Feb 04, 2025

Feb 04, 2025

Mineralys completes enrollment for hypertension drug trial - MSN

Feb 04, 2025

Feb 04, 2025

Mineralys Completes Enrollment in Mid-Stage Hypertension Trial -February 04, 2025 at 11:43 am EST - Marketscreener.com

Feb 04, 2025